| pubmed-article:18301889 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18301889 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18301889 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:18301889 | lifeskim:mentions | umls-concept:C0278678 | lld:lifeskim |
| pubmed-article:18301889 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:18301889 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
| pubmed-article:18301889 | lifeskim:mentions | umls-concept:C1514468 | lld:lifeskim |
| pubmed-article:18301889 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:18301889 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:18301889 | lifeskim:mentions | umls-concept:C0205250 | lld:lifeskim |
| pubmed-article:18301889 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:18301889 | pubmed:dateCreated | 2008-8-26 | lld:pubmed |
| pubmed-article:18301889 | pubmed:abstractText | gamma9delta2 T lymphocytes have been shown to be directly cytotoxic against renal carcinoma cells. Lymphocytes T gammadelta can be selectively expanded in vivo with BrHPP (IPH1101, Phosphostim) and interleukin 2 (IL-2). A phase I Study was conducted in patients with metastatic renal cell carcinoma (mRCC) to determine the maximum-tolerated dose and safety of Innacell gammadelta, an autologous cell-therapy product based on gamma9delta2 T lymphocytes, in patients with mRCC. | lld:pubmed |
| pubmed-article:18301889 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18301889 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18301889 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18301889 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18301889 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18301889 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18301889 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18301889 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:18301889 | pubmed:issn | 0340-7004 | lld:pubmed |
| pubmed-article:18301889 | pubmed:author | pubmed-author:BennounaJaafa... | lld:pubmed |
| pubmed-article:18301889 | pubmed:author | pubmed-author:TiollierJérôm... | lld:pubmed |
| pubmed-article:18301889 | pubmed:author | pubmed-author:BompasEmmanue... | lld:pubmed |
| pubmed-article:18301889 | pubmed:author | pubmed-author:NégrierSylvie... | lld:pubmed |
| pubmed-article:18301889 | pubmed:author | pubmed-author:RollandFrédér... | lld:pubmed |
| pubmed-article:18301889 | pubmed:author | pubmed-author:AudrainMarieM | lld:pubmed |
| pubmed-article:18301889 | pubmed:author | pubmed-author:SaiaghSorayaS | lld:pubmed |
| pubmed-article:18301889 | pubmed:author | pubmed-author:RimbertMarieM | lld:pubmed |
| pubmed-article:18301889 | pubmed:author | pubmed-author:PhilipIrèneI | lld:pubmed |
| pubmed-article:18301889 | pubmed:author | pubmed-author:SalotSamuelS | lld:pubmed |
| pubmed-article:18301889 | pubmed:author | pubmed-author:NeidhardtEve... | lld:pubmed |
| pubmed-article:18301889 | pubmed:author | pubmed-author:GaléaCélineC | lld:pubmed |
| pubmed-article:18301889 | pubmed:author | pubmed-author:Lafaye-de... | lld:pubmed |
| pubmed-article:18301889 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18301889 | pubmed:volume | 57 | lld:pubmed |
| pubmed-article:18301889 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18301889 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18301889 | pubmed:pagination | 1599-609 | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:meshHeading | pubmed-meshheading:18301889... | lld:pubmed |
| pubmed-article:18301889 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18301889 | pubmed:articleTitle | Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. | lld:pubmed |
| pubmed-article:18301889 | pubmed:affiliation | Department of Medical Oncology, Centre René Gauducheau, Nantes-Saint-Herblain, France. j-bennouna@nantes.fnclcc.fr | lld:pubmed |
| pubmed-article:18301889 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18301889 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18301889 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18301889 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18301889 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18301889 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18301889 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18301889 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18301889 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18301889 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18301889 | lld:pubmed |
